Ramucirumab + Docetaxel + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urothelial Carcinoma
Conditions
Urothelial Carcinoma
Trial Timeline
Jul 13, 2015 → Jul 26, 2022
NCT ID
NCT02426125About Ramucirumab + Docetaxel + Placebo
Ramucirumab + Docetaxel + Placebo is a phase 3 stage product being developed by Eli Lilly for Urothelial Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02426125. Target conditions include Urothelial Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02426125 | Phase 3 | Completed |
Competing Products
20 competing products in Urothelial Carcinoma